RxDoctor Payments Data

Suzanne Higgins, APRN

Family · Jacksonville, ARNPI 1578841441

Payments from drug & device makers

$831in general payments, 2019–2025

Across 31 payments — averaging $26.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$468
  • AbbVie$187
  • Smith+Nephew$35
  • Organon$25
  • KCI USA, Inc.$18
  • Insulet Corporation$18
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$831100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$831 in reported general payments places this provider in the 65th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$445
Medicare patients
27
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$55,016
JardianceEmpagliflozin44$31,142
MounjaroTirzepatide16$20,331
EliquisApixaban23$16,518
Janumet XrSitagliptin Phos/Metformin Hcl18$15,364
Breo ElliptaFluticasone/Vilanterol22$9,100
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,107
Albuterol Sulfate HfaAlbuterol Sulfate67$1,895
Gentamicin Sulfate34$1,530
Atorvastatin Calcium156$1,391
Novolin RInsulin Regular, Human11$1,352
Estradiol14$1,165
ValacyclovirValacyclovir Hcl12$985
Metoprolol Succinate69$897
Amlodipine Besylate113$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$31,14244 claims
Lilly USA, LLCMounjaro$18$20,33116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,103 family providers in Arkansas.

Other family in Jacksonville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →